Treatment with a highly reducing agent decreases ubiquitination of D_4.2R WT and D_{4.2 4KR}R mutant. by Kamila Skieterska (841014)

Inhibition of Hsp90 abolished VEGF-mediated eNOS phosphorylation and decreased NO production and cell viability in BAECs. by Yuanzhuo Chen (802891)

Decrease of Paneth cells in mice fed a high-fat diet (HFD). by June-Chul Lee (2850536)

<i>Cin85</i>-Deficiency results in defective clearance of LCMV-c13 and is correlated with decreased neutralizing antibody titer. by Saravanan Raju (5181014)

V3Nter decreases colony formation and induces tumor cell death in HCT116 and HepG2 cells. by Delphine Quélard (43727)

Deletion of <i>sagA</i> alone results in a decrease in nasopharyngeal infection. by Blake A. Shannon (14197601)

Promoter reporter studies for reported <i>NR5A1</i> mutations by Jana Malikova (615672)

Subjects:

Knockdown of NRP1 increases while knockdown of NRP2 decreases formation of Schwann cell clusters. by Kasper C. D. Roet (444802)

“…<p>(A–C) Representative SC clusters when co-cultured with MCs for 5 days after a transfection with siGlo, siNRP1 pool or siNRP2 pool respectively. …”

GCase activity is significantly decreased in the brain and liver of the homozygous <i>GBA1</i> D409V KI mouse model at 4, 8, and 12 months of age. by Nicole K. Polinski (10947787)

“…In whole brain homogenate (A,C) and liver homogenate (B,D), GCase activity is significantly decreased in the <i>GBA1</i> D409V KI homozygous (HOM) mice as compared to C57Bl/6 wild type (WT) mice (n = 7/group). …”

Brain and liver GCase activity are significantly decreased in heterozygous <i>GBA1</i> D409V KI mice, with varying differences in glucosphingolipid lipids in brain and liver. by Nicole K. Polinski (10947787)

“…<p>(A-B) GCase, (C-D) gluocosylceramide (GlcCer), and (E-F) glucosylsphingosine (GlcSph) levels measured in whole brain homogenate and liver homogenate of C57Bl/6 wild type (WT) and <i>GBA1</i> D409V KI heterozygous (HET) mice at 5 months of age (n = 10/age). …”

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects: